OrbiMed’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

OrbiMed’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,466,783	Closed	-$2.31K	–	137
2022 Q3	$2.31K	Hold	8,466,783	–	–	0.04%	121
2022 Q2	$2.97K	Hold	8,466,783	–	–	0.05%	122
2022 Q1	$5.76M	Hold	8,466,783	–	–	0.09%	117
2021 Q4	$19.6M	Hold	8,466,783	–	–	0.25%	86
2021 Q3	$38.8M	Hold	8,466,783	–	–	0.43%	65
2021 Q2	$37.6M	Hold	8,466,783	–	–	0.38%	70
2021 Q1	$61.6M	Hold	8,466,783	–	–	0.58%	50
2020 Q4	$64.6M	Buy	8,466,783 +2,000,000	+31%	+$13.4M	0.57%	50
2020 Q3	$58.7M	Hold	6,466,783	–	–	0.74%	38
2020 Q2	$54.7M	Hold	6,466,783	–	–	0.77%	42
2020 Q1	$31.9M	Hold	6,466,783	–	–	0.54%	49
2019 Q4	$46.6M	Hold	6,466,783	–	–	0.66%	48
2019 Q3	$69.9M	Hold	6,466,783	–	–	1.33%	25
2019 Q2	$84.1M	Hold	6,466,783	–	–	1.3%	22
2019 Q1	$63.9M	Hold	6,466,783	–	–	0.99%	33
2018 Q4	$67.3M	Buy	+6,466,783	New	+$78.1M	1.24%	25

OrbiMed's LOGC Position: Q4 2022 in Review

OrbiMed sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 8,466,783 shares — an estimated $2.31K sold.

OrbiMed first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $84.1M in Q2 2019. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

OrbiMed reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
OrbiMed sold 8,466,783 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $2.31K.
OrbiMed first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
OrbiMed's LogicBio Therapeutics, Inc. Common Stock position peaked at $84.1M in Q2 2019.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.